Quantitative analysis of persister fractions suggests different mechanisms of formation among environmental isolates of E. coli

BMC Microbiology

Volumn 13, Issue 1, 2013, Pages

  Hofsteenge, Niels ^a   Van Nimwegen, Erik ^a   Silander, Olin K ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Ampicillin; Antibiotic; Ciprofloxacin; E. coli; Environmental isolates; Nalidixic acid; Persister

Indexed keywords

CIPROFLOXACIN; NALIDIXIC ACID;

ARTICLE; BACTERIAL CELL; BACTERIUM ISOLATE; CELL FUNCTION; CELL SURVIVAL; ESCHERICHIA COLI; NONHUMAN; PHENOTYPE; QUANTITATIVE ANALYSIS;

ANTI-BACTERIAL AGENTS; ENVIRONMENTAL MICROBIOLOGY; ESCHERICHIA COLI; MICROBIAL VIABILITY; MODELS, THEORETICAL;

BACTERIA (MICROORGANISMS);

EID: 84873183509     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-13-25     Document Type: Article

References (39)

1. Treatment of staphylococcal infections with penicillin-by intermittent sterilisation. Bigger JW, Lancet 1944 2 497 500
2. The challenge of treating biofilm-associated bacterial infection. del Pozo JL, Patel R, Clin Pharmacol Ther 2007 82 2 204 209 10.1038/sj.clpt.6100247 17538551
3. Persister cells. Lewis K, Annu Rev Microbiol 2010 64 357 372 10.1146/annurev.micro.112408.134306 20528688
4. Emergence of pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. Mulcahy LR, Burns JL, Lory S, Lewis K, J Bacteriol 2010 192 23 6191 6199 10.1128/JB.01651-09 20935098
5. The rate of killing of escherichia-coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial-growth. Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A, J Gen Microbiol 1986 132 1297 1304 3534137
6. Bacterial persistence as a phenotypic switch. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S, Science 2004 305 5690 1622 1625 10.1126/science. 1099390 15308767
7. Specialized persister cells and the mechanism of multidrug tolerance in escherichia coli. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K, J Bacteriol 2004 186 24 8172 8180 10.1128/JB.186.24.8172-8180.2004 15576765
8. Persisters: a distinct physiological state of E-coli. Shah D, Zhang ZG, Khodursky A, Kaldalu N, Kurg K, Lewis K, BMC Microbiology 2006 6 53 10.1186/1471-2180-6-53 16768798
9. Persister cells, dormancy and infectious disease. Lewis K, Nat Rev Microbiol 2007 5 1 48 56 10.1038/nrmicro1557 17143318
10. SOS response induces persistence to fluoroquinolones in escherichia coli. Dorr T, Lewis K, Vulic M, PLoS Genet 2009 5 12 1000760 10.1371/journal.pgen. 1000760 20011100
11. Bacterial persistence by RNA endonucleases. Maisonneuve E, Shakespeare LJ, Jorgensen MG, Gerdes K, P Natl Acad Sci USA 2011 108 32 13206 13211 10.1073/pnas.1100186108
12. Hipa, a newly recognized gene of escherichia-coli K-12 that affects frequency of persistence after inhibition of murein synthesis. Moyed HS, Bertrand KP, J Bacteriol 1983 155 2 768 775 6348026
13. Ectopic overexpression of wild-type and mutant hipA genes in escherichia coli: effects on macromolecular synthesis and persister formation. Korch SB, Hill TM, J Bacteriol 2006 188 11 3826 3836 10.1128/JB.01740-05 16707675
14. Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice. Dhar N, McKinney JD, P Natl Acad Sci USA 2010 107 27 12275 12280 10.1073/pnas.1003219107
15. The three RelE homologs of mycobacterium tuberculosis have individual, drug-specific effects on bacterial antibiotic tolerance. Singh R, Barry CE, Boshoff HIM, J Bacteriol 2010 192 5 1279 1291 10.1128/JB.01285-09 20061486
16. Characterization and transcriptome analysis of mycobacterium tuberculosis persisters. Keren I, Minami S, Rubin E, Lewis K, Mbio 2011 2 3 00100 11 21673191
17. Antioxidant strategies to tolerate antibiotics. Belenky P, Collins JJ, Science 2011 334 6058 915 916 10.1126/science.1214823 22096180
18. Genetic variation for antibiotic persistence in escherichia coli. Stewart B, Rozen DE, Evolution 2012 66 3 933 939 10.1111/j.1558-5646.2011.01467.x 22380453
19. Mutants of escherichia-coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents. Wolfson JS, Hooper DC, Mchugh GL, Bozza MA, Swartz MN, Antimicrob Agents Ch 1990 34 10 1938 1943 10.1128/AAC.34.10.1938
20. The frequency of persisters in escherichia coli reflects the kinetics of awakening from dormancy. Joers A, Kaldalu N, Tenson T, J Bacteriol 2010 192 13 3379 3384 10.1128/JB.00056-10 20435730
21. Age of inoculum strongly influences persister frequency and Can mask effects of mutations implicated in altered persistence. Luidalepp H, Joers A, Kaldalu N, Tenson T, J Bacteriol 2011 193 14 3598 3605 10.1128/JB.00085-11 21602347
22. Oxidation of the guanine nucleotide pool underlies cell death by bactericidal antibiotics. Foti JJ, Devadoss B, Winkler JA, Collins JJ, Walker GC, Science 2012 336 6079 315 319 10.1126/science.1219192 22517853
23. Antibiotic treatment in vitro of phenotypically tolerant bacterial populations. Wiuff C, Andersson DI, J Antimicrob Chemoth 2007 59 2 254 263
24. GlpD and PlsB participate in persister cell formation in Eschetichia coli. Spoering AL, Vulic M, Lewis K, J Bacteriol 2006 188 14 5136 5144 10.1128/JB.00369-06 16816185
25. Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli. Hansen S, Lewis K, Vulic M, Antimicrob Agents Ch 2008 52 8 2718 2726 10.1128/AAC.00144-08
26. Presence and growth of naturalized Escherichia coli in temperate soils from lake superior watersheds. Ishii S, Ksoll WB, Hicks RE, Sadowsky MJ, Appl Environ Microb 2006 72 1 612 621 10.1128/AEM.72.1.612-621.2006
27. Genome sequencing of environmental Escherichia coli expands understanding of the ecology and speciation of the model bacterial species. Luo CW, Walk ST, Gordon DM, Feldgarden M, Tiedje JM, Konstantinidis KT, P Natl Acad Sci USA 2011 108 17 7200 7205 10.1073/pnas.1015622108
28. Quinolones: a comprehensive review. Oliphant CM, Green GM, Am Fam Physician 2002 65 3 455 464 11858629
29. Kinase activity of overexpressed HipA is required for growth arrest and multidrug tolerance in Escherichia coli. Correia FF, D'Onofrio A, Rejtar T, Li LY, Karger BL, Makarova K, Koonin EV, Lewis K, J Bacteriol 2006 188 24 8360 8367 10.1128/JB.01237-06 17041039
30. Increased persistence in Escherichia coli caused by controlled expression of toxins or other unrelated proteins. Vazquez-Laslop N, Lee H, Neyfakh AA, J Bacteriol 2006 188 10 3494 3497 10.1128/JB.188.10.3494-3497.2006 16672603
31. Mode of action of the New quinolones-New data. Hooper DC, Wolfson JS, Eur J Clin Microbiol 1991 10 4 223 231 10.1007/BF01966994
32. Mechanisms of resistance to quinolones. Jacoby GA, Clin Infect Dis 2005 41 120 S126 10.1086/428052 15942878
33. The constancy of gene conservation across divergent bacterial orders. Silander OK, Ackermann M, BMC Research Notes 2009 2 2 10.1186/1756-0500-2-2 19128452
34. Pharmacodynamics, population dynamics and the evolution of persistence in staphylococcus aureus. Johnson PJT, Levin BR, PLoS Genet 2013 in press
35. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR, Antimicrob Agents Ch 2004 48 10 3670 3676 10.1128/AAC.48.10.3670-3676.2004
36. Single-cell protein induction dynamics reveals a period of vulnerability to antibiotics in persister bacteria. Gefen O, Gabay C, Mumcuoglu M, Engel G, Balaban NQ, P Natl Acad Sci USA 2008 105 16 6145 6149 10.1073/pnas.0711712105
37. Relationship between spontaneous aminoglycoside resistance in Escherichia coli and a decrease in oligopeptide binding protein. Kashiwagi K, Tsuhako MH, Sakata K, Saisho T, Igarashi A, da Costa SOP, Igarashi K, J Bacteriol 1998 180 20 5484 5488 9765586
38. Automated imaging with ScanLag reveals previously undetectable bacterial growth phenotypes. Levin-Reisman I, Gefen O, Fridman O, Ronin I, Shwa D, Sheftel H, Balaban NQ, Nat Methods 2010 7 9 737 U100 10.1038/nmeth.1485 20676109
39. R: a language and environment for statistical computing http://www.R-project.org